Alkermes (ALKS) Stock Price, News & Analysis

Company Overview

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products. Vivitrol, a once-monthly injectable therapy for the prevention of relapse to opioid dependence following detoxification and for the treatment of alcohol dependence, represents one of the company’s cornerstone offerings. In partnership with other pharmaceutical firms, Alkermes also supports the development and commercialization of therapies such as ARISTADA (aripiprazole lauroxil) for schizophrenia and Lybalvi (olanzapine/samidorphan) for schizophrenia and bipolar I disorder. These collaborations leverage Alkermes’ formulation and delivery platforms to optimize drug release profiles and enhance patient adherence.

The company’s research and development efforts are anchored by two proprietary drug delivery platforms: ALKS 2680 microsphere technology for sustained-release injectable formulations and ATRIGEL depot technology for biodegradable, polymer-based delivery. Alkermes’ R&D pipeline includes a diverse array of small molecules and biologics targeting CNS disorders, with programs in varying stages of clinical development. These assets reflect the company’s commitment to advancing long-acting therapies that can reduce dosing frequency and improve the overall patient experience.

Established in 1987, Alkermes maintains dual headquarters in Dublin, Ireland, and Waltham, Massachusetts, and operates manufacturing facilities in Ireland and the United States. The company’s leadership is headed by Chief Executive Officer Richard F. Pops, who has overseen its growth from a research-stage enterprise into a global biopharmaceutical organization. Alkermes continues to collaborate with academic institutions, patient advocacy groups and industry partners to expand access to therapies for CNS disorders worldwide.

Key Stats

• Today's Range: $36.58 to $37.26
• 50-Day Range: $27.20 to $38.91
• 52-Week Range: $25.17 to $39.56
• Volume: 907,753 shs
• Average Volume: 2.15 million shs
• Market Capitalization: $6.13 billion
• P/E Ratio: 40.89
• Dividend Yield: N/A
• Price Target: $45.40
• Consensus Rating: Moderate Buy

Alkermes Stock Analysis - MarketRank™

Alkermes scored higher than 51% of companies evaluated by MarketBeat, and ranked 493rd out of 866 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Alkermes has received a consensus rating of Moderate Buy. The company's average rating score is 2.76, and is based on 1 strong buy rating, 11 buy ratings, 5 hold ratings, and no sell ratings.

Upside Potential

Alkermes has a consensus price target of $45.40, representing about 23.4% upside from its current price of $36.80.

Amount of Analyst Coverage

Alkermes has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Alkermes are expected to grow in the coming year, from ($0.43) to $0.55 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Alkermes is 40.89, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.98.

Price to Earnings Ratio vs. Sector

The P/E ratio of Alkermes is 40.89, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 21.02.

Price to Book Value per Share Ratio

Alkermes has a P/B Ratio of 3.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.43% of the float of Alkermes has been sold short.

Short Interest Ratio / Days to Cover

Alkermes has a short interest ratio ("days to cover") of 12.55, which indicates bearish sentiment.

Change versus previous month

Short interest in Alkermes has recently increased by 0.39%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Alkermes does not currently pay a dividend.

Dividend Growth

Alkermes does not have a long track record of dividend growth.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.27

News Sentiment

Alkermes has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Alkermes this week, compared to 6 articles on an average week.

Search Interest

Only 1 people have searched for ALKS on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.

MarketBeat Follows

4 people have added Alkermes to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Alkermes insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,265,090.00 in company stock.

Percentage Held by Insiders

4.59% of the stock of Alkermes is held by insiders.

Percentage Held by Institutions

95.21% of the stock of Alkermes is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 2/14/2026
• Today: 5/23/2026
• Next Earnings (Estimated): 7/28/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ALKS
• CIK: 1520262
• Web: www.alkermes.com
• Phone: (531) 772-8000
• Fax: 781-890-0524
• Employees: 2,050
• Year Founded: 1987

Price Target and Rating

• Average Price Target for Alkermes: $45.40
• High Price Target: $56.00
• Low Price Target: $35.00
• Potential Upside/Downside: +23.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.76
• Research Coverage: 17 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.90
• Trailing P/E Ratio: 40.89
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $241.66 million
• Net Margins: 9.78%
• Pretax Margin: 13.06%
• Return on Equity: 9.26%
• Return on Assets: 5.66%

Debt

• Debt-to-Equity Ratio: 0.85
• Current Ratio: 2.27
• Quick Ratio: 1.70

Sales & Book Value

• Annual Sales: $1.48 billion
• Price / Sales: 4.16
• Cash Flow: $1.67 per share
• Price / Cash Flow: 22.07
• Book Value: $10.51 per share
• Price / Book: 3.50

Miscellaneous

• Outstanding Shares: 166,680,000
• Free Float: 159,026,000
• Market Cap: $6.13 billion
• Optionable: Optionable
• Beta: 0.31